Today, Paxman publishes the June issue of its newsletter aimed at shareholders, investors and other interested parties.

This month’s issue highlights that the American Medical Association (AMA) resolved to advocate for and seek through legislation and/or regulation, universal insurance coverage for scalp cooling therapy at the annual meeting for its principal policy-making body House of Delegates (HOD). At the meeting, AMA also resolved to work with consumer and advocacy groups to challenge insurers on medical necessity denials for scalp cooling therapy and encourage appeals of such decisions.

The newsletter also includes information on that Paxman celebrated five successful years in the US at the recent ASCO annual meeting, this month’s orders and installations in the US, the UK and rest of the world including 10 systems to Japan, that Paxman won the National Medilink UK Award for Outstanding Achievement, and the fourth episode of the Changing the Face of Cancer podcast where the chemotherapy side effect CIPN is discussed.

To read the newsletter and subscribe for upcoming issues, follow this link:

https://bit.ly/paxjun22en

Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on Paxman’s website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 4,400 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company’s Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

Paxman publishes newsletter on AMA resolutions to advocate for universal insurance coverage of scalp cooling

© Modular Finance, source Nordic Press Releases